| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Other liabilities | -212,316 | - |
| Net cash used in operating activities | -4,772,494 | -3,531,230 |
| Proceeds from borrowings on notes payable | 500,000 | 500,000 |
| Proceeds from borrowings on notes payable - related parties | 100,000 | 100,000 |
| Proceeds from sales of common stock | 2,410,356 | 1,085,785 |
| Proceeds from sales of series b convertible preferred stock | 100,000 | 100,000 |
| Proceeds from exercise of warrants | 927,000 | 630,000 |
| Proceeds from exercise of warrants | - | 1,150,000 |
| Collection of subscriptions receivable | 1,150,000 | - |
| Net cash provided by financing activities | 5,187,356 | 3,565,785 |
| End of period | 414,862 | 34,555 |
| Cash and cash equivalents at beginning of period | 58,653 | 58,653 |
| Effect of exchange rate changes on cash | 7,766 | 7,811 |
| Cash and cash equivalents at end of period | 481,281 | 101,019 |
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)